Claims
- 1. A compound of formula (I)
- 2. The compound of claim 1 wherein
Z1 is —CR4—; Z3 is —CR6—; and Z4 is —CR7—.
- 3. The compound of claim 2 wherein
Z2 is —CR5—; R1 is hydrogen; R2 is —LR8; and m is 0.
- 4. The compound of claim 3 wherein X is —N—.
- 5. The compound of claim 3 wherein X is —CR3—.
- 6. The compound of claim 5 wherein L is selected from the group consisting of —(CH2)nC(O)(CH2)p—, —C≡C—(CH2)nO—, —C(O)NR9—, —NR9C(O)—, —NR9—, —NR9C(S)NR10—, —NR9C(═NCN)NR10—, —NR9C(═NCN)O, and NR9SO2—.
- 7. The compound of claim 5 wherein L is —(CH2)nNR9C(O)NR10(CH2)p—.
- 8. The compound of claim 7 wherein n and p are 0.
- 9. The compound of claim 8 wherein R8 is aryl.
- 10. The compound of claim 9 wherein R3 is selected from the group consisting of alkenyl, alkoxyalkyl, arylalkyl, halo, heteroarylalkyl, heterocyclylalkyl, hydroxyalkyl, and (NRaRb)alkyl.
- 11. The compound of claim 9 wherein R3 is (NRaRb)C(O)alkyl.
- 12. The compound of claim 9 wherein R3 is hydrogen.
- 13. The compound of claim 9 wherein R3 is alkyl.
- 14. The compound of claim 13 wherein the alkyl is selected from the group consisting of ethyl, isopropyl, and propyl.
- 15. The compound of claim 13 wherein the alkyl is methyl.
- 16. A compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N′-[2-fluoro-5-(trifluoromethyl)phenyl]urea.
- 17. A compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N′-(3-methylphenyl)urea.
- 18. A compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N′-(3-chlorophenyl)urea.
- 19. A compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N′-[3-(trifluoromethyl)phenyl]urea.
- 20. A compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N′-[3-(trifluoromethyl)phenyl]urea.
- 21. A pharmaceutical composition comprising a compound of claim 1 or a therapeutically acceptable salt thereof, in combination with a therapeutically acceptable carrier.
- 22. A method for inhibiting a protein kinase in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of claim 1, or a therapeutically acceptable salt thereof.
- 23. A method for inhibiting KDR in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of claim 1, or a therapeutically acceptable salt thereof.
- 24. A method for inhibiting Tie-2 in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of claim 1, or a therapeutically acceptable salt thereof.
- 25. A method for treating cancer in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of claim 1, or a therapeutically acceptable salt thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. Patent Application Ser. No. 10/103,621, filed on Mar. 21, 2002, which is hereby incorporated by reference.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10103621 |
Mar 2002 |
US |
Child |
10378481 |
Mar 2003 |
US |